Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Immunovant, Inc. (IMVT) had Income from Continuous Operations of $-505.61M for the most recently reported fiscal year, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-505.61M |
|
-- |
|
-- |
|
$532.90M |
|
$-532.90M |
|
$27.51M |
|
$-505.39M |
|
$-505.39M |
|
$-505.61M |
|
|
Income from Continuous Operations |
$-505.61M |
$-505.61M |
|
$-505.61M |
|
$-532.90M |
|
$-532.49M |
|
182.42M |
|
182.42M |
|
$-2.77 |
|
$-2.77 |
|
| Balance Sheet Financials | |
$948.82M |
|
$0.44M |
|
$8.20M |
|
$957.01M |
|
$104.42M |
|
-- |
|
-- |
|
$104.42M |
|
$852.59M |
|
$852.59M |
|
$852.59M |
|
203.94M |
|
| Cash Flow Statement Financials | |
$-407.31M |
|
$-0.01M |
|
$595.76M |
|
$713.97M |
|
$902.11M |
|
$188.14M |
|
$55.72M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-407.32M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-59.30% |
|
-59.30% |
|
-52.83% |
|
-59.30% |
|
$4.18 |
|
$-2.23 |
|
$-2.23 |
|